Skip to Main Content
Lael Yonker, M.D.

Lael Yonker, M.D.

Titles and Appointments

Chief, Division of Pediatric Pulmonology and Sleep Medicine

Associate Professor & Division Chief

Endowed Title
Pogue Distinguished Chair in Pediatric Pulmonology Medicine
Schools
Medical School
Departments
Pediatrics

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Lael Yonker, M.D., is an Associate Professor in the Department of Pediatrics at UT Southwestern Medical Center. Dr. Yonker also holds the Pogue Distinguished Chair in Pediatric Pulmonology Medicine.

    Dr. Yonker joined the UT Southwestern faculty in 2025. She is certified by the American Board of Pediatrics. Previously, Dr. Yonker was a faculty member at Mass General Brigham, where she was director of the Cystic Fibrosis Center, co-director of the Cystic Fibrosis Therapeutic Development Center, co-director of the Pulmonary Genetics Program, and principal investigator for the Pediatric COVID-19 Biorepository.

    Dr. Yonker earned her medical degree at the University of Massachusetts. She completed a residency in pediatrics and received advanced training through a pediatric pulmonary fellowship, both at Mass General Brigham. She is a member of several professional societies including, the American Academy of Pediatrics, American Thoracic Society, and Massachusetts Medical Society.

    As a physician-scientist, Dr. Yonker integrates clinical pulmonary care with translational research to improve outcomes for children with complex respiratory disease. Her work bridges mechanistic studies in patient-derived samples with hypothesis‑driven clinical trials to identify and interrupt maladaptive inflammatory pathways. The goal of her scientific program is to define infection-driven mechanisms that lead to airway and systemic disease in children and leverage‑ these insights to develop targeted therapies. Dr. Yonker specializes in pediatric pulmonary disease and cystic fibrosis.

    Dr. Yonker contributes to national and international medical leadership through service with the Cystic Fibrosis Foundation and the American Thoracic Society. She has contributed foundational insights into post–COVID‑19 inflammatory syndromes, co‑invented a diagnostic method for a monocytic biomarker used to identify COVID‑19-related illness, and patented therapeutic strategies for multisystem inflammatory syndrome in children.

    In 2024, she earned the Emerging Leader Award from the National Academy of Medicine.

  • Publications
    Multisystem Inflammatory Syndrome in Children: A Comprehensive Review Over the Past Five Years
    Shyong O, Alfakhri N, Bates SV, Carroll RW, Gallagher K, Huang L, Madhavan V, Murphy SA, Okrzesik SA, Yager PH, Yonker LM, Lok J Journal of Intensive Care Medicine 2026 Apr 41 284-308
    Severe Bleomycin-Induced Pneumonitis Following Localized Injection in a Child With a TERT Variant and Short Telomeres
    Okuducu Y, Verwillow A, Fracchia MS, Abulhamail A, Yonker L, Nelson BA, Bernard Kinane T Pediatric pulmonology 2026 Mar 61
    Phage-Based Approaches to Chronic Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis
    Hwang W, Yong JH, Lenneman BR, Yonker LM Antibiotics 2026 Feb 15
    Expansion of variant panels in newborn screening algorithms to identify cystic fibrosis: A retrospective analysis of 25 years of genotypes and implications on diagnosis
    Hale JE, O’Sullivan BP, Parad RB, Dorkin HL, Kremer TM, Vehse NW, Yonker LM, Sawicki GS, Counihan AM, Gerstel-Thompson J, Kumar B, Comeau AM Genetics in Medicine 2026 Jan 28
    Life between breaths: quality of life in children’s interstitial and diffuse lung disease
    Liptzin DR, McDowell MD, Yonker LM European Respiratory Journal 2026 67
    Endovascular profiles linked to neutrophil activation in children and young adults with long COVID
    Steifman CB, Alvarez-Carcamo B, Verma S, McCarthy R, Guthrie LB, Gill KK, Swank Z, Walt DR, Grabowski EF, Fasano A, VanElzakker MB, Irimia D, Yonker LM Pediatric Research 2026
    Illness Burden in Adults With Cystic Fibrosis: Associations With Sex, Race/Ethnicity, and Socioeconomic Risk Factors
    DiFiglia S, Georgiopoulos AM, Seng EK, Portenoy R, Chaudhary N, Yonker LM, Wang J, Walker P, Stables-Carney T, Middour-Oxler B, Linnemann RW, Kier C, Friedman D, Berdella MN, Dhingra L Pediatric pulmonology 2025 Oct 60
    Monocyte Anisocytosis Can Discriminate between Sepsis and Sterile Inflammation, but not Mortality, in Critically Ill Surgical/Trauma Patients: A Secondary Prospective Analysis
    Hernández-Ríos M, Wu R, Polcz VA, Burnside RD, Yonker LM, Irimia D, Xiao F, Rincon JC, Loftus TJ, Moldawer LL, Maile R, Efron PA, Liang M Critical Care Explorations 2025 Sep 7 e1309
    NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa
    Truong-Bolduc QC, Wang Y, Lawton BG, Zweifach JJ, McDevitt GM, Abdellaoui YE, Harding HB, Yonker LM, Rahme LG, Vyas JM, Hooper DC Antimicrobial agents and chemotherapy 2025 Aug 69
    Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide
    Yonker LM, Kane AS, Swank Z, Papadakis L, Kenyon V, Han S, Lima R, Guthrie LB, Alvarez-Carcamo B, Lahoud-Rahme M, Balaguru D, Carroll RW, Lok J, El Saleeby C, Walt DR, Fasano A Science translational medicine 2025 Jul 17